Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.

  • Revenue in USD (TTM)30.07bn
  • Net income in USD2.09bn
  • Incorporated1925
  • Employees47.35k
  • Location
    Takeda Pharmaceutical Co Ltd4F, 2-1-1, Nihombashihon-choCHUO-KU 103-8668JapanJPN
  • Phone+81 332782111
  • Fax+81 332782000
  • Websitehttps://www.takeda.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
4502:TYO since
Nimbus Lakshmi IncAnnounced13 Dec 202213 Dec 2022Announced2.96%6.00bn
Shionogi & Co Ltd-Intuniv & Vyvanse Manufacturing & Sales BusinessAnnounced31 Oct 202231 Oct 2022Announced8.76%--
Data delayed at least 20 minutes, as of Feb 03 2023 06:00 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Gartner Inc5.28bn760.34m27.02bn16.60k36.88--,918.8011.254.1220.197.0669.3465.0014.416.65--15.861.03--15.4814.13197.5032.603.71--
Alnylam Pharmaceuticals, Inc.960.92m-1.18bn28.71bn1.67k------29.88-9.77-9.777.95-0.54990.27431.456.86577,127.90-33.74-32.56-42.04-37.9483.85---123.02-223.643.33-2.761.07--71.3178.070.6358--3.42--
DuPont de Nemours Inc14.18bn1.16bn36.26bn28.00k31.891.4614.552.562.293.6327.8450.150.31483.545.49506,571.402.71-0.22273.11-0.289235.0531.608.62-1.611.995.110.3173--16.15-19.13172.14-15.09-25.20-26.30
Iqvia Holdings Inc14.31bn1.18bn44.05bn85.00k38.608.2419.773.086.156.1574.4328.780.593--5.76181,101.304.941.776.252.1434.7234.308.343.64--5.160.69860.0022.1415.28246.2468.0831.30--
Takeda Pharmaceutical Co Ltd (ADR)30.07bn2.09bn51.30bn47.35k23.701.057.241.710.67380.67389.6715.140.30111.435.54635,151.402.101.862.482.2468.5068.856.966.980.7463.410.4097123.9411.6115.56-38.8114.8910.680.00
Moderna Inc21.39bn11.77bn66.56bn2.70k6.263.735.503.1127.6527.6550.6946.490.91062.937.337,922,222.0050.0941.1777.8866.7879.20--55.0052.351.80--0.05990.002,199.12179.441,733.33--53.67--
Data as of Feb 03 2023. Currency figures normalised to Takeda Pharmaceutical Co Ltd's reporting currency: US Dollar USD

Institutional shareholders

0.96%Per cent of shares held by top holders
HolderShares% Held
Mondrian Investment Partners Ltd.as of 30 Sep 20224.75m0.15%
Clal Pension & Provident Funds Ltd.as of 30 Sep 20224.34m0.14%
Parametric Portfolio Associates LLCas of 30 Sep 20224.21m0.13%
Macquarie Investment Management Business Trustas of 30 Sep 20223.99m0.13%
Renaissance Technologies LLCas of 30 Sep 20222.85m0.09%
Aperio Group LLCas of 30 Sep 20222.23m0.07%
Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 20222.19m0.07%
Goldman Sachs Asset Management LPas of 30 Sep 20221.97m0.06%
Strategic Advisers LLCas of 30 Sep 20221.96m0.06%
Brandes Investment Partners LPas of 30 Sep 20221.87m0.06%
More ▼
Data from 30 Sep 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.